| ipilimumab based treatment | ipilimumab alone | ipilimumab based treatment | nivolumab based treatment | pembrolizumab alone |
| ipilimumab alone | Ipilimumab (10 mg/kg) | ipilimumab plus gp100 | ipilimumab plus SoC | nivolumab alone | pembrolizumab (10mg/kg) | pembrolizumab (10mg/kg) 2 weeks | pembrolizumab (2mg/kg) |
mML - L2 - all population 11 | | | | | | | | |
Comparator:
vs ipilimumab alone; vs gp100; vs placebo plus SoC; vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;